Cargando…

Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery

This study examined infectious outcomes in elective colorectal cancer surgery between cefotetan alone or conventional triple antibiotics. From January to December 2007, 461 consecutive primary colorectal cancer patients underwent elective surgery. Group A contained 225 patients who received conventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Woon Kyung, Park, Ji Won, Lim, Seok-Byung, Choi, Hyo Seong, Jeong, Seung-Yong
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826745/
https://www.ncbi.nlm.nih.gov/pubmed/20191043
http://dx.doi.org/10.3346/jkms.2010.25.3.429
_version_ 1782177884757032960
author Jeong, Woon Kyung
Park, Ji Won
Lim, Seok-Byung
Choi, Hyo Seong
Jeong, Seung-Yong
author_facet Jeong, Woon Kyung
Park, Ji Won
Lim, Seok-Byung
Choi, Hyo Seong
Jeong, Seung-Yong
author_sort Jeong, Woon Kyung
collection PubMed
description This study examined infectious outcomes in elective colorectal cancer surgery between cefotetan alone or conventional triple antibiotics. From January to December 2007, 461 consecutive primary colorectal cancer patients underwent elective surgery. Group A contained 225 patients who received conventional triple antibiotics (cephalosporin, aminoglycoside and metronidazole) for prophylaxis, and group B contained 236 patients who received cefotetan alone for prophylaxis. Treatment failure was defined as the presence of postoperative infection including surgical-site infection (SSI), anastomotic leakage, and pneumonia or urinary tract infection. The two groups were similar in terms of demographics, American Society of Anesthesiologists (ASA) score, tumour location, stage, surgical approach (conventional open vs. laparoscopy-assisted), and type of operation. The treatment failure rates were 3.1% in Group A and 3.4% in Group B (absolute difference, -0.3%; 95% confidence interval [CI], 0.39 to 3.07, P=0.866), with SSI being the most common reason for failure in both groups (2.7% in Group A and 3.0% in Group B [absolute difference, -0.3%; 95% CI, 0.37 to 3.37, P=0.846]). Cefotetan alone is as effective as triple antibiotics for prophylaxis in primary colorectal cancer patients undergoing elective surgery.
format Text
id pubmed-2826745
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-28267452010-03-01 Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery Jeong, Woon Kyung Park, Ji Won Lim, Seok-Byung Choi, Hyo Seong Jeong, Seung-Yong J Korean Med Sci Original Article This study examined infectious outcomes in elective colorectal cancer surgery between cefotetan alone or conventional triple antibiotics. From January to December 2007, 461 consecutive primary colorectal cancer patients underwent elective surgery. Group A contained 225 patients who received conventional triple antibiotics (cephalosporin, aminoglycoside and metronidazole) for prophylaxis, and group B contained 236 patients who received cefotetan alone for prophylaxis. Treatment failure was defined as the presence of postoperative infection including surgical-site infection (SSI), anastomotic leakage, and pneumonia or urinary tract infection. The two groups were similar in terms of demographics, American Society of Anesthesiologists (ASA) score, tumour location, stage, surgical approach (conventional open vs. laparoscopy-assisted), and type of operation. The treatment failure rates were 3.1% in Group A and 3.4% in Group B (absolute difference, -0.3%; 95% confidence interval [CI], 0.39 to 3.07, P=0.866), with SSI being the most common reason for failure in both groups (2.7% in Group A and 3.0% in Group B [absolute difference, -0.3%; 95% CI, 0.37 to 3.37, P=0.846]). Cefotetan alone is as effective as triple antibiotics for prophylaxis in primary colorectal cancer patients undergoing elective surgery. The Korean Academy of Medical Sciences 2010-03 2010-02-17 /pmc/articles/PMC2826745/ /pubmed/20191043 http://dx.doi.org/10.3346/jkms.2010.25.3.429 Text en © 2010 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jeong, Woon Kyung
Park, Ji Won
Lim, Seok-Byung
Choi, Hyo Seong
Jeong, Seung-Yong
Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery
title Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery
title_full Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery
title_fullStr Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery
title_full_unstemmed Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery
title_short Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery
title_sort cefotetan versus conventional triple antibiotic prophylaxis in elective colorectal cancer surgery
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826745/
https://www.ncbi.nlm.nih.gov/pubmed/20191043
http://dx.doi.org/10.3346/jkms.2010.25.3.429
work_keys_str_mv AT jeongwoonkyung cefotetanversusconventionaltripleantibioticprophylaxisinelectivecolorectalcancersurgery
AT parkjiwon cefotetanversusconventionaltripleantibioticprophylaxisinelectivecolorectalcancersurgery
AT limseokbyung cefotetanversusconventionaltripleantibioticprophylaxisinelectivecolorectalcancersurgery
AT choihyoseong cefotetanversusconventionaltripleantibioticprophylaxisinelectivecolorectalcancersurgery
AT jeongseungyong cefotetanversusconventionaltripleantibioticprophylaxisinelectivecolorectalcancersurgery